Drug's benefit to younger breast cancer patients in question

The bisphosphonate zoledronic acid did not improve survival rates for patients with early-stage breast cancer except among women who were five or more years past menopause, study finds.A class of drugs that has been increasingly used to treat breast cancer in recent years may not improve survival rates in younger women with the disease, researchers reported Thursday.

Read the whole article on LA Times - Science

More from LA Times - Science